Because of the failure of early detection by ovarian cancer screening, current guidelines recommend risk-reducing salpingo-oophorectomy (RRSO) at the age of 35–40 years for BRCA1 mutation carriers and at 40–45 years for BRCA2 mutation carriers as a standard approach to decrease the incidence of cancer among these women [10]. The gene discussed is BRCA2; the disease is ovarian carcinoma.